HLA-DPβ1 Asp84-Lys69 antigen-binding signature predicts event-free survival in childhood B-cell precursor acute lymphoblastic leukaemia: results from the MRC UKALL XI childhood ALL trial

[1]  R. Wade,et al.  No association of HLA‐A supertype with outcome in childhood acute lymphoblastic leukaemia: results of the UKALL XI trial , 2011, British journal of haematology.

[2]  Claire Schwab,et al.  Acute lymphoblastic leukaemia. , 2011, Methods in molecular biology.

[3]  R. Altman,et al.  Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. , 2010, The Lancet. Oncology.

[4]  S. Richards,et al.  Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. , 2010, The Lancet. Oncology.

[5]  Bjoern Peters,et al.  Five HLA-DP Molecules Frequently Expressed in the Worldwide Human Population Share a Common HLA Supertypic Binding Specificity , 2010, The Journal of Immunology.

[6]  R. Wade,et al.  The impact of risk stratification by early bone‐marrow response in childhood lymphoblastic leukaemia: results from the United Kingdom Medical Research Council trial ALL97 and ALL97/99 , 2009, British journal of haematology.

[7]  G. M. Taylor,et al.  Strong association of the HLA-DP6 supertype with childhood leukaemia is due to a single allele, DPB1*0601 , 2009, Leukemia.

[8]  G. M. Taylor,et al.  Relationship between HLA‐DP supertype and survival in childhood acute lymphoblastic leukaemia: evidence for selective loss of immunological control of residual disease? , 2009, British journal of haematology.

[9]  C. Hawrylowicz,et al.  Regulatory T cells in bronchial asthma , 2009, Allergy.

[10]  L. Silverman,et al.  Childhood acute lymphoblastic leukemia: update on prognostic factors , 2009, Current opinion in pediatrics.

[11]  Cheng Cheng,et al.  Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. , 2009, JAMA.

[12]  Martin Stanulla,et al.  Treatment of childhood acute lymphoblastic leukemia. , 2009, Seminars in hematology.

[13]  D. Campana.  Status of minimal residual disease testing in childhood haematological malignancies , 2008, British journal of haematology.

[14]  M. Loh,et al.  Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study , 2008, Leukemia.

[15]  G. M. Taylor,et al.  HLA-associated susceptibility to childhood B-cell precursor ALL: definition and role of HLA-DPB1 supertypes , 2008, British Journal of Cancer.

[16]  S. Oka,et al.  Pharmacogenetic information derived from analysis of HLA alleles. , 2008, Pharmacogenomics.

[17]  M. Tanimoto,et al.  Loss or down‐regulation of HLA class I expression at the allelic level in freshly isolated leukemic blasts , 2007, Cancer science.

[18]  M. Greaves,et al.  HLA-DPB1 supertype-associated protection from childhood leukaemia: relationship to leukaemia karyotype and implications for prevention , 2007, Cancer Immunology, Immunotherapy.

[19]  George Davidson,et al.  Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. , 2006, Blood.

[20]  W. Zou.  Regulatory T cells, tumour immunity and immunotherapy , 2006, Nature Reviews Immunology.

[21]  C. Pui,et al.  Treatment of acute lymphoblastic leukemia. , 2006, The New England journal of medicine.

[22]  P. Gaynon.  Childhood acute lymphoblastic leukaemia and relapse , 2005, British journal of haematology.

[23]  S. Richards,et al.  Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial , 2005, British journal of haematology.

[24]  C. Akdis,et al.  Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. , 2004, The Journal of allergy and clinical immunology.

[25]  S. Davies,et al.  Pharmacogenetics of acute lymphoblastic leukemia , 2004, Current opinion in hematology.

[26]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[27]  P. Kourilsky,et al.  Foxp3 Expressing CD4+CD25high Regulatory T Cells Are Overrepresented in Human Metastatic Melanoma Lymph Nodes and Inhibit the Function of Infiltrating T Cells1 , 2004, The Journal of Immunology.

[28]  P. Maes,et al.  Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack? , 2004, Blood.

[29]  Alexander A Morley,et al.  Evidence for whole chromosome 6 loss and duplication of the remaining chromosome in acute lymphoblastic leukemia , 2003, Genes, chromosomes & cancer.

[30]  M. Amicosante,et al.  Functional analysis of HLA-DP polymorphism: a crucial role for DPbeta residues 9, 11, 35, 55, 56, 69 and 84-87 in T cell allorecognition and peptide binding. , 2003, International immunology.

[31]  Alain Sanson,et al.  HLA-DP4, the Most Frequent HLA II Molecule, Defines a New Supertype of Peptide-Binding Specificity1 , 2002, The Journal of Immunology.

[32]  G. M. Taylor,et al.  Genetic susceptibility to childhood common acute lymphoblastic leukaemia is associated with polymorphic peptide-binding pocket profiles in HLA-DPB1*0201. , 2002, Human molecular genetics.

[33]  Mel Greaves,et al.  The United Kingdom Childhood Cancer Study: objectives, materials and methods , 2000 .

[34]  박민호,et al.  The United Kingdom Childhood Cancer Study: objectives, materials and methods , 2000, British Journal of Cancer.

[35]  H. Fujita,et al.  Augmentation of immune response by altered peptide ligands of the antigenic peptide in a human CD4+ T-cell clone reacting to TEL/AML1 fusion protein. , 1999, Tissue antigens.

[36]  J. Chessells,et al.  Improved survival with early intensification: combined results from the Medical Research Council childhood ALL randomised trials, UKALL X and UKALL XI , 1998, Leukemia.

[37]  R. Foà,et al.  Immunophenotype of adult and childhood acute lymphoblastic leukemia: changes at first relapse and clinico-prognostic implications , 1997, Leukemia.

[38]  J. Kersey.  Fifty years of studies of the biology and therapy of childhood leukemia. , 1997, Blood.

[39]  R. Pieters,et al.  Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. , 1996, Medical and pediatric oncology.

[40]  J. V. van Dongen,et al.  Immunophenotypic changes between diagnosis and relapse in childhood acute lymphoblastic leukemia. , 1995, Leukemia.

[41]  P Wordsworth,et al.  Critical role for the Val/Gly86 HLA-DR beta dimorphism in autoantigen presentation to human T cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[42]  J. Rothbard,et al.  Effect of natural polymorphism at residue 86 of the HLA-DR beta chain on peptide binding. , 1991, Journal of immunology.

[43]  G. Schreuder,et al.  Random HLA-DR distribution in children with acute lymphocytic leukaemia in long-term continuous remission. , 1982 .

[44]  V. Piaskowski,et al.  Association between HLA-D region antigens and disease-free survival in childhood non-T, non-B acute lymphocytic leukemia. , 1982, Blood.

[45]  H. Sather,et al.  Immunologic evaluation in the prognosis of acute lymphoblastic leukemia. A report from Childrens Cancer Study Group. , 1981, Blood.

[46]  T. Révész,et al.  THE ASSOCIATION OF HLA‐DR5 ANTIGEN WITH LONGER SURVIVAL IN CHILDHOOD LEUKAEMIA , 1981, British journal of haematology.

[47]  J. Stockman,et al.  HLA Antigens and Childhood Acute Lymphocytic Leukaemia , 1981, British journal of haematology.

[48]  G. Sokal,et al.  HLA Haplotypes and Long Survival in Childhood Acute Lymphoblastic Leukaemia Treated with Transfer Factor , 1980, British journal of haematology.

[49]  M. Lipinski,et al.  HLA phenotypes in long-term survivors treated with BCG immunotherapy for childhood ALL. , 1978, British medical journal.

[50]  J. Burchenal,et al.  Treatment of acute lymphoblastic leukemia. , 1972, Annual review of medicine.

[51]  Blood Cancer Journal , 2022 .